{"filing":{"accession_number":"0001477932-26-005351","cik":"0000093314","ticker":"VNRX","company_name":"VOLITIONRX LTD","form":"8-K","filing_date":"2026-09-01","report_date":"2026-08-27","primary_document":"vnrx_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/93314/000147793226005351/vnrx_8k.htm"},"events":[{"id":31119,"run_id":28543,"accession_number":"0001477932-26-005351","anchor_item_number":"3.02","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"The filing discloses multiple unregistered issuances of common stock by VolitionRx to Lind Global Asset Management in satisfaction of conversion obligations under senior secured convertible promissory notes. Across seven separate transactions in late August 2026, the Company issued approximately 4.4 million shares (712,328 + 520,547 + 698,630 + 695,890 + 693,151 + 690,411 + 687,671 shares) representing roughly $1.465 million in aggregate conversion value. These conversions are explicitly disclosed under Item 3.02 and rely on Section 3(a)(9), Section 4(a)(2), and Rule 506(d) exemptions—hallmarks of dilutive private equity issuances. The scale and frequency of these conversions, combined with the existing convertible debt structure, signal material dilution to existing shareholders.","company_name":"VOLITIONRX LTD","ticker":"VNRX","filing_date":"2026-09-01","form":"8-K","submitted_at":null,"items":[{"id":33921,"accession_number":"0001477932-26-005351","item_number":"3.02","item_title":"Unregistered Sales of Equity Securities","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"The filing discloses multiple unregistered issuances of common stock by VolitionRx to Lind Global Asset Management in satisfaction of conversion obligations under senior secured convertible promissory notes. Across seven separate transactions in late August 2026, the Company issued approximately 4.4 million shares (712,328 + 520,547 + 698,630 + 695,890 + 693,151 + 690,411 + 687,671 shares) representing roughly $1.465 million in aggregate conversion value. These conversions are explicitly disclosed under Item 3.02 and rely on Section 3(a)(9), Section 4(a)(2), and Rule 506(d) exemptions—hallmarks of dilutive private equity issuances. The scale and frequency of these conversions, combined with the existing convertible debt structure, signal material dilution to existing shareholders.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-02T10:07:51.700224+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":33921,"accession_number":"0001477932-26-005351","item_number":"3.02","item_title":"Unregistered Sales of Equity Securities","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"The filing discloses multiple unregistered issuances of common stock by VolitionRx to Lind Global Asset Management in satisfaction of conversion obligations under senior secured convertible promissory notes. Across seven separate transactions in late August 2026, the Company issued approximately 4.4 million shares (712,328 + 520,547 + 698,630 + 695,890 + 693,151 + 690,411 + 687,671 shares) representing roughly $1.465 million in aggregate conversion value. These conversions are explicitly disclosed under Item 3.02 and rely on Section 3(a)(9), Section 4(a)(2), and Rule 506(d) exemptions—hallmarks of dilutive private equity issuances. The scale and frequency of these conversions, combined with the existing convertible debt structure, signal material dilution to existing shareholders.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-02T10:07:51.700224+00:00","company_name":"VOLITIONRX LTD","ticker":"VNRX","filing_date":"2026-09-01"}]}